1. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413–20.
2. CDER/FDA. Guidance for industry: waiver of in vivo bioavailability and bioequivalence studies for immediate release dosage forms based on a biopharmaceutical classification system, Center for Drug Evaluation and Research; 2000 At:
www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070246.pdf
. Accessed 18 June 2012.
3. Dahan A, Miller JM, Amidon GL. Prediction of solubility and permeability class membership: provisional BCS classification of the world’s top oral drugs. AAPS J. 2009;11:740–6.
4. WHO. Proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms. Annex 8 of WHO Expert Committee on Specifications for Pharmaceutical Preparations. Geneva: WHO Technical Report Series No. 937, 2006; 40th edition: pp 391–461. At:
http://www.who.int/medicines/publications/essentialmedicines/en/index.html
. Accessed 18 June 2012.
5. CDER/FDA. Guidance for industry: immediate release solid oral dosage forms: scale-up and postapproval changes: chemistry, manufacturing and controls, in vitro dissolution testing, and in vivo bioequivalence documentation, Center for Drug Evaluation and Research; 1995. At:
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070636.pdf
. Accessed 18 June 2012.